FDA Approves Zenflow Spring Implant and Delivery System for BPH
December 12, 2025
The Spring is the only FDA-approved FIT in a range of lengths and diameters, allowing for patient personalisation
The Spring is the only FDA-approved FIT in a range of lengths and diameters, allowing for patient personalisation
A European research project led by VTT has developed machine vision mimicking the cooperation of the eye and nervous system, implemented as edge-computing circuits.
PLANO, Texas, Dec. 11, 2025 /PRNewswire/ — Vesalio, a leader in thrombectomy solutions, today announced FDA 510(k) clearance and the upcoming U.S. commercial launch of enVast™, the first and only clot retriever specifically cleared for mechanical thrombectomy in the cardiac circulation. enVast introduces a proven, innovative approach to clot capture and removal, redefining coronary thrombectomy for patients with large thrombus burden (LTB).
An interdisciplinary research team from Dresden University of Technology (TUD), Rostock University Medical Center (UMR) and Dresden University Hospital has developed an innovative, implantable and fully absorbable sensor film.
A study published in the Journal of Clinical Oncology confirms that one of the first Food and Drug Administration-approved CAR-T cell therapies offers long-term survival and potential cures for adult patients with relapsed or refractory large B-cell lymphoma, even years after treatment.
Heart muscle cells grown from patient stem cells—known as human induced pluripotent stem cell–derived cardiomyocytes, or hiPSC-CMs—are a promising way to repair hearts damaged by heart attacks and heart failure.
Neurovalens announced that it received FDA de novo approval for Modius Lean, its non-invasive neurotechnology for weight management.
Flow Neuroscience’s at-home depression treatment device has become the first of its kind to be approved by the FDA.
Lumos Labs’ LumosityRx is positioned for use alongside other ADHD treatment modalities such as medication and therapy.
GRAND BLANC, Mich., Dec. 10, 2025 /PRNewswire/ — ModuleMD, ranked as one of America’s fastest-growing companies on the Inc. 5000 and top-rated EHR vendor on G2, announces SkinSight™ AI, a solution that brings automation, accuracy, and consistency to one of the most manual and variable workflows in allergy care: skin test measurement and documentation.